Bionano Genomics (Nasdaq: BNGO) is a San Diego-based life sciences instrumentation company that sells the Saphyr and Stratys systems for optical genome mapping (OGM), a technique used to detect structural variants in DNA that conventional methods can miss.
Only two current, attributable analyst targets could be verified. Maxim Group's Jason McCarthy reiterated a Buy rating with a $4 target in late May 2026, while H.C. Wainwright's Yi Chen lowered his target to $6 from $7 in April 2026 while keeping a Buy. The arithmetic mean of these two figures is $5.00, which is the central target used here. The range is wide—$4 to $6—which, on a sub-$2 stock, is a meaningful spread of opinion.
Both analysts lean constructive, but their reasoning differs on pace rather than direction: the lower target reflects a more conservative view on how fast OGM utilization and instrument placements translate into durable revenue, while the higher target assigns more credit to reimbursement progress and expanding clinical evidence. Notably, neither target implies a consensus in the traditional sense, since coverage is thin. A third data source, Weiss Ratings, recently issued an upgrade, but it does not publish a price target comparable to the two brokerage figures above.
The stock closed near $1.16, toward the low end of its 52-week range of roughly $1.00 to $2.23, with a market capitalization around $14 million. Reaching $5 would require an advance of approximately 330%—an extremely large move that would represent a re-rating of the entire company rather than a routine step higher.
The path would almost certainly depend on sustained, accelerating revenue growth and progress toward profitability. The company reported 21% revenue growth and a 53% gross margin in its second quarter of 2026, raised its full-year outlook, and guided to $8.2–$8.6 million in third-quarter revenue. Trailing-twelve-month revenue was about $30 million against a net loss of roughly $32 million, so the business remains firmly unprofitable on an EPS (earnings per share) basis. A move toward $5 would require investors to price in years of future adoption today.
The most credible supports are operational and regulatory. New York State's Department of Health approval of OGM-based lab developed tests (LDTs) and a proposed MolDX local coverage determination for structural-variant testing in blood cancers both point toward reimbursement, a key hurdle for clinical adoption. Peer-reviewed studies from institutions such as MD Anderson Cancer Center continue to show OGM detecting abnormalities that karyotyping and FISH miss. The company also retired its senior secured convertible debentures in May 2026, simplifying the balance sheet.
If utilization among existing customers keeps growing and reimbursement expands, the revenue multiple the market assigns to BNGO could expand—though that is an interpretation, not a forecast.
The obstacles are substantial. The company's auditor, BDO LLP, expressed doubt about Bionano's ability to continue as a going concern in the 2025 Form 10-K, citing funding and liquidity risk. The company has repeatedly raised capital, including a registration filing in late 2026 tied to warrant exercises, which can dilute existing shareholders. With a market cap near $14 million and short interest reported at roughly 18% of the float, the stock is vulnerable to sharp swings. Any slowdown in instrument placements, weaker consumable pull-through, or a dilution event could keep the shares anchored well below $5.
The $1.00 level has acted as a notable psychological and technical floor, marking the lower bound of the 52-week range. The $2.20–$2.25 zone, the prior year's high, stands out as the first major overhead resistance a sustained rally would need to clear. Because the stock trades on very low float and high relative volume, technical levels can shift quickly and should be treated cautiously rather than as reliable support or resistance.
Analyst price targets generally reflect a research horizon of about 12 months, though the two covering firms do not publish identical assumptions, and neither horizon is guaranteed. The most immediate catalyst is the company's third-quarter 2026 report, scheduled for November 10, 2026. Investors should watch revenue and guidance, gross margin, cash runway and any financing announcements, reimbursement decisions, and any change to the going-concern language in subsequent filings.
For traders tracking names like BNGO, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to keep pace with changing conditions. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from evolving market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to surface new opportunities, monitor existing positions, and spot shifting trends more efficiently than scanning charts manually. Explore the AI Daily Buy/Sell Signals to see how automated monitoring can complement your own research process.
Whether Bionano Genomics can reach $5 ultimately depends on execution that has not yet been proven. The target—the mean of a $4 Maxim Group view and a $6 H.C. Wainwright view—implies roughly 330% upside from current levels, an extremely demanding move for a micro-cap company that is still losing money and carries a going-concern warning. The bullish case rests on real momentum: rising revenue, gross-margin improvement, reimbursement approvals, and an expanding body of clinical evidence for OGM. The bearish case is equally concrete: thin cash, recurring dilution, and a share structure that leaves little margin for error. The two analysts disagree meaningfully on pace, and with only two targets available, no firm "analyst consensus" should be inferred. What to watch next is straightforward: the quarterly report, cash runway, and whether reimbursement and utilization growth can outpace the company's need for capital.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that BNGO and RGEN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNGO and RGEN's prices will move in lockstep.
| Ticker / NAME | Correlation To BNGO | 1D Price Change % | ||
|---|---|---|---|---|
| BNGO | 100% | -3.85% | ||
| RGEN - BNGO | 31% Poorly correlated | +0.76% | ||
| ARAY - BNGO | 30% Poorly correlated | -9.09% | ||
| PACB - BNGO | 29% Poorly correlated | -0.51% | ||
| VIVO - BNGO | 29% Poorly correlated | +3.24% | ||
| DRIO - BNGO | 28% Poorly correlated | -23.64% | ||
More | ||||
| Ticker / NAME | Correlation To BNGO | 1D Price Change % |
|---|---|---|
| BNGO | 100% | -3.85% |
| Pharmaceuticals: Other industry (49 stocks) | 19% Poorly correlated | +0.20% |
| Pharmaceuticals industry (151 stocks) | 10% Poorly correlated | +0.11% |